Pharmapremia Oncology Success Rates Scorecard

DESCRIPTION Over the past five years, oncology drug development has increased dramatically as a proverbial arms-race accelerated into the immune-oncology space. Some of the biggest names in Pharma began development internally, and scoured the globe for in-licensing and acquisition candidates to stake their claim to the next-generation of cancer standard of care. With Oncology drug...

Immuno-Oncology Deal Trends, 2012–16

DESCRIPTION Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups signed more than 300 immuno-oncology deals between 2012 and 2016, growing at...

NOACs Pricing, Reimbursement, and Access

DESCRIPTION A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers. The impact of NOACs on European budgets is so great that a UK payer...

Global Influenza Drugs and Vaccines Market – By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) – Analysis By Region, By Country: Opportunities and Forecast (2016-2021)- – By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan)

EXECUTIVE SUMMARY A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Influenza Market on the basis of Segment Type (Vaccine and Drugs), By Vaccine (Trivalent and Quadrivalent), By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Region (North America,...

Q4 2016 Outlook Report – Cover Catalysts from 23 Drugs, Devices and Diagnostics

In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q4 2016. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular...

Pharma & Healthcare Newsletter

Pharma & Healthcare Newsletter Subscription Subscription Period: One Year Price: Now Only @ $106.99 / Year We offer Industry specific News Updates. We work really hard to provide you with real time, reliable & authentic information services. We offer Pharma & Healthcare Newsletter Subscription to fulfill your corporate requirements and needs to stay updated with...

Pharmaceuticals & Healthcare – Upcoming & Recent Reports

OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-... Published: May’ 2017       Format: Electronic PDF       Pricing:...

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

“Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered...

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals

“Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered...